{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:32:21Z","timestamp":1785843141248,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.leukres.2022.106949","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:59:35Z","timestamp":1662465575000},"page":"106949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy"],"prefix":"10.1016","volume":"122","author":[{"given":"Yanhua","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunyuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.leukres.2022.106949_bib3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.leukres.2022.106949_bib4","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2022.106949_bib5","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00262-020-02806-2","article-title":"CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration","volume":"70","author":"Shi","year":"2021","journal-title":"Cancer Immunol., Immunother. CII"},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12885-021-08045-7","article-title":"CD47 expression and CD163(+) macrophages correlated with prognosis of pancreatic neuroendocrine tumor","volume":"21","author":"Imam","year":"2021","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2022.106949_bib7","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/cam4.2882","article-title":"Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer","volume":"9","author":"Arrieta","year":"2020","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat. Immunol."},{"issue":"7655","key":"10.1016\/j.leukres.2022.106949_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"7769","key":"10.1016\/j.leukres.2022.106949_bib10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"issue":"63","key":"10.1016\/j.leukres.2022.106949_bib11","doi-asserted-by":"crossref","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.leukres.2022.106949_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.leukres.2022.106949_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2141.2007.06729.x","article-title":"Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma","volume":"138","author":"Rendtlew Danielsen","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2022.106949_bib14","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2022.106949_bib15","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2022.106949_bib16","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3324\/haematol.2019.227579","article-title":"Targeting CD47\/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma","volume":"105","author":"Rastgoo","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2022.106949_bib19","article-title":"CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies","volume":"16","author":"Sun","year":"2021","journal-title":"Leuk. Res. Rep."},{"issue":"6","key":"10.1016\/j.leukres.2022.106949_bib20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \"don't eat me\" signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"issue":"10","key":"10.1016\/j.leukres.2022.106949_bib21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000413","article-title":"The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a","volume":"8","author":"Peluso","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2022.106949_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.leukres.2004.09.005","article-title":"Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma","volume":"29","author":"Kikuchi","year":"2005","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2022.106949_bib24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.leukres.2022.106949_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020057118","article-title":"DLL1 orchestrates CD8(+) T cells to induce long-term vascular normalization and tumor regression","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.leukres.2022.106949_bib26","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-019-0713-x","article-title":"The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo","volume":"12","author":"Zhou","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"33","key":"10.1016\/j.leukres.2022.106949_bib28","doi-asserted-by":"crossref","first-page":"24219","DOI":"10.1074\/jbc.M701565200","article-title":"Dual regulation of SIRPalpha phosphorylation by integrins and CD47","volume":"282","author":"Johansen","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2022.106949_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, mechanisms, and significance of macrophage plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CCO.0b013e32831bed7e","article-title":"Corrupt policemen: inflammatory cells promote tumor angiogenesis","volume":"21","author":"Zumsteg","year":"2009","journal-title":"Curr. Opin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106949_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2022.106949_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008850","article-title":"Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma","volume":"4","author":"Calcinotto","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.leukres.2022.106949_bib34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2022.106949_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cam4.1283","article-title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.leukres.2022.106949_bib36","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2022.106949_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1182\/blood-2016-03-704460","article-title":"A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy","volume":"128","author":"Lin","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2022.106949_bib38","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2022.106949_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12032-020-01426-1","article-title":"Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro","volume":"37","author":"Sun","year":"2020","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106949_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10456-013-9381-6","article-title":"Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo","volume":"17","author":"Jetten","year":"2014","journal-title":"Angiogenesis"},{"issue":"5706","key":"10.1016\/j.leukres.2022.106949_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.leukres.2022.106949_bib42","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-06-0323","article-title":"Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma","volume":"12","author":"Martin","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2022.106949_bib43","first-page":"800","article-title":"Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood","volume":"85","author":"Di Raimondo","year":"2000","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.leukres.2022.106949_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.leukres.2022.106949_bib45","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","article-title":"Perivascular M2 macrophages stimulate tumor relapse after chemotherapy","volume":"75","author":"Hughes","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2022.106949_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.placenta.2017.03.021","article-title":"Angiopoietin 2 in placentation and tumor biology: the yin and yang of vascular biology","volume":"56","author":"Wang","year":"2017","journal-title":"Placenta"},{"issue":"4","key":"10.1016\/j.leukres.2022.106949_bib47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccr.2011.02.005","article-title":"Targeting the ANG2\/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells","volume":"19","author":"Mazzieri","year":"2011","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.leukres.2022.106949_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094570","article-title":"Functions of thrombospondin-1 in the tumor microenvironment","volume":"22","author":"Kaur","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.leukres.2022.106949_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2004-831051","article-title":"Platelet factor 4: an inhibitor of angiogenesis","volume":"30","author":"Bikfalvi","year":"2004","journal-title":"Semin. Thromb. Hemost."},{"issue":"7652","key":"10.1016\/j.leukres.2022.106949_bib50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature22311","article-title":"Tumour ischaemia by interferon-\u03b3 resembles physiological blood vessel regression","volume":"545","author":"Kammertoens","year":"2017","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1016\/j.leukres.2023.107068","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000}}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T15:41:57Z","timestamp":1711122117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":50,"alternative-id":["S0145212622001758"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106949","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.leukres.2023.107068","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106949"}}